Suppression of Metastatic Ovarian Cancer Cells by Bepridil, a Calcium Channel Blocker

Although surgery followed by platinum-based therapy is effective as a standard treatment in the early stages of ovarian cancer, the majority of cases are diagnosed at advanced stages, leading to poor prognosis. Thus, the identification of novel therapeutic drugs is needed. In this study, we assessed the effectiveness of bepridil-a calcium channel blocker-in ovarian cancer cells using two cell lines: SKOV-3, and SKOV-3-13 (a highly metastatic clone of SKOV-3). Treatment of these cell lines with bepridil significantly reduced cell viability, migration, and invasion. Notably, SKOV-3-13 was more sensitive to bepridil than SKOV-3. The TGF-& beta;1-induced epithelial-mesenchymal transition (EMT)-like phenotype was reversed by treatment with bepridil in both cell lines. Consistently, expression levels of EMT-related markers, including vimentin, & beta;-catenin, and Snail, were also substantially decreased by the treatment with bepridil. An in vivo mouse xenograft model was used to confirm these findings. Tumor growth was significantly reduced by bepridil treatment in SKOV-3-13-inoculated mice, and immunohistochemistry showed consistently decreased expression of EMT-related markers. Our findings are the first to report anticancer effects of bepridil in ovarian cancer, and they suggest that bepridil holds significant promise as an effective therapeutic agent for targeting metastatic ovarian cancer.

Automated summary

In this study, the effectiveness of bepridil, a calcium channel blocker, in ovarian cancer cells was assessed. The study found that bepridil significantly reduced cell viability, migration, and invasion, and reversed the TGF-β1-induced epithelial-mesenchymal transition (EMT)-like phenotype. In an in vivo mouse xenograft model, bepridil treatment significantly reduced tumor growth. These findings suggest that bepridil holds promise as an effective therapeutic agent for metastatic ovarian cancer.